Suppr超能文献

体外对多药耐药蛋白1(MDR1)转导的造血细胞进行药物选择可增加转基因表达,并提高小鼠重建骨髓中的化疗耐药性。

Drug selection of MDR1-transduced hematopoietic cells ex vivo increases transgene expression and chemoresistance in reconstituted bone marrow in mice.

作者信息

Licht T, Goldenberg S K, Vieira W D, Gottesman M M, Pastan I

机构信息

Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4255, USA.

出版信息

Gene Ther. 2000 Feb;7(4):348-58. doi: 10.1038/sj.gt.3301087.

Abstract

The MDR1 (multidrug resistance) gene, transferred to hematopoietic cells, is expected to protect them from anticancer chemotherapy and may serve as a selectable marker, restoring gene expression in vivo. Appropriate selection strategies, however, need to be established. To investigate whether preselection ex vivo affects chemoresistance, murine bone marrow cells were retrovirally transduced with high-titer or, as a model for suboptimal gene expression, low-titer retroviruses and exposed to daunomycin or colchicine for 48-96 h. Selection significantly increased chemoresistance of clonogenic progenitor cells. In tissue culture, the entire target population was rendered highly drug resistant after MDR1 transfer with high-titer viruses. If transduction was performed under suboptimal conditions, drug selection increased the frequency of chemoresistant colonies up to 40% over the number of unselected cells. Colchicine and daunomycin were equally efficient in increasing drug resistance ex vivo, but colchicine-preselected cells rescued lethally irradiated mice under conditions where daunomycin-selected bone marrow cells failed to do so. Hence, while hematopoietic cells can be protected by MDR1, the selection strategy is critical for repopulation of bone marrow with transduced cells. Preselection in culture before transplantation significantly increased P-gp expression and chemoresistance in vivo in mice reconstituted with transduced bone marrow cells. This study may help to facilitate the use of MDR1 as a selectable marker in gene therapy of the hematopoietic system. Gene Therapy (2000) 7, 348-358.

摘要

多药耐药(MDR1)基因转移至造血细胞后,有望保护这些细胞免受抗癌化疗药物的影响,并可作为一种选择标记,在体内恢复基因表达。然而,需要建立合适的选择策略。为了研究体外预选择是否会影响化疗耐药性,用高滴度逆转录病毒或作为基因表达欠佳模型的低滴度逆转录病毒对小鼠骨髓细胞进行逆转录病毒转导,并使其暴露于柔红霉素或秋水仙碱中48 - 96小时。选择显著增加了克隆形成祖细胞的化疗耐药性。在组织培养中,用高滴度病毒进行MDR1转移后,整个靶细胞群体都具有高度耐药性。如果在欠佳条件下进行转导,药物选择使化疗耐药集落的频率比未选择细胞的数量增加了40%。秋水仙碱和柔红霉素在体外增加耐药性方面同样有效,但在柔红霉素选择的骨髓细胞无法挽救致死性照射小鼠的条件下,秋水仙碱预选择的细胞却能做到。因此,虽然造血细胞可被MDR1保护,但选择策略对于用转导细胞重建骨髓至关重要。移植前在培养中进行预选择显著增加了用转导骨髓细胞重建的小鼠体内P - 糖蛋白的表达和化疗耐药性。本研究可能有助于促进MDR1在造血系统基因治疗中作为选择标记的应用。《基因治疗》(2000年)7卷,348 - 358页 。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验